Overview
Lobbying Costs
37,500€
Financial year: Jan 2019 - Dec 2019
Lobbyists (Full time equivalent)
0.75 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
8
Lobbying Costs over the years
-
Info
European Organisation for Research and Treatment of Cancer (EORTC)
EU Transparency Register
70539554035-46 First registered on 20 Aug 2010
Goals / Remit
The European Organisation for Research and Treatment of Cancer (EORTC) is the largest independent cancer clinical research organization. The EORTC has delivered investigator driven, changing practice clinical trials since 1962. Its mission is to improve survival and quality of life of cancer patients. The EORTC is a not-for-profit independent organisation performing multidisciplinary clinical research activities across tumor types. EORTC’s activities involve on a voluntary basis more than 5300 medical doctors and scientists from 930 university hospitals in 36 countries. EORTC clinical trials are involving several thousands of patients on a yearly basis.
Main EU files targeted
- Regulation on clinical trials on medicinal products for human use.
-Regulation on Health Technology Assessment.
-Early access to medicines: PRIME, accelerated assessment, conditional market authorization.
- Good Clinical Practice implementation.
- General Data Protection Regulation.
- Regulation of the European Parliament and of the Council on in vitro diagnostic medical devices.
- Euratom and radioprotection.
- EU Beating Cancer plan.
- EU Cancer mission.
- EU Roadmap for a pharmaceutical strategy for Europe.
- EU Partnership for Health Innovation.Address
Head Office
avenue Mounier, 83
Brussels 1200
BELGIUM -
People
Total lobbyists declared
3
Employment time Lobbyists 25% 3 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
III - Non-governmental organisations
Subcategory
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
European CanCer Organisation
European Forum for Good Clinical Practice
European Alliance for Personnalised Medicine
European Association for NeuroOncology
European Association of Urology
European School of Oncology
European Association of Urology
American Association for Cancer Research
European Society for Therapeutic Radiology and Oncology
European Society for Medical Oncology
American Society for Therapeutic Radiology and Oncology
International Society of Geriatric Oncology
International Society of Pediatric Oncology
International Union Against Cancer
International Network for Cancer Research and Treatment
Organisation of European Cancer Institutes
European Oncology Nursing Society
European Society of Pathology
European Society of RadiologyMember organisations
Our members are medical doctors and/or scientists affiliated to university hospitals that are participating to EORTC clinical and translational research activities.
http://www.eortc.org/members/ -
Financial Data
Closed financial year
Jan 2019 - Dec 2019
Lobbying costs for closed financial year
37,500€
EU grant income for closed financial year
326,000 € (Source: FP7,H2020, IMI)
Other financial info
The EORTC Cancer Research Fund (ECRF) is an independent non-profit association founded in 1976 under the honorary presidency of His Royal Highness Prince Philip, the Duke of Edinburgh. ECRF’s objective is to promote, encourage and support research on the treatment of cancer. To fulfil this, it engages in financing studies and research performed by the international non-profit organisation, EORTC.
Funds come from grants and donations from institutional, corporate partnerships, private and public foundations, individual private donors, legacies and organisations’ in financial or in-kind donations to EORTC’s activities.
Every single donation goes in full to specific EORTC projects chosen either by the donor or in the case of an unrestricted gift, by the EORTC to cancer research that lacks funding. In both cases, donors are able to follow and be part of EORTC’s journey in increasing survival and quality of life for all cancer patients.
In addition, grants for EORTC research projects are received from the European Commission Research Framework Programmes FP7 and H2020.
Clinical studies evaluating new drugs for potential registration or testing innovative therapeutic agents, including some educational projects, are conducted in cooperation with pharmaceutical industry partners in strict compliance with EORTC criteria for independence. Pharmaceutical industry financial support is also provided in the form of “unrestricted grants” for EORTC conferences.
The finances of the EORTC includes all accounts from the EORTC Headquarters as well as all EORTC Groups. These accounts are consolidated as required under Belgian Law. The EORTC accounts are audited by Ernst & Young.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
Cancer
Communication activities
Participation in workshops and conference involving EU institutions officials. Position statement in collaboration with stakeholders groups such European Cancer Organisation, European Alliance for Personalised Medicine, BioMedAlliance, Rare Cancers Europe, EFGCP, European Data in Health Research Alliance, , European Federation of Pharmaceutical Industries, EuropaBio, FIPRA.
Other activities
- International investigator-driven clinical trials
- Funding independent clinical research.
- Human biological material for use in research
- Secondary use of clinical data.
- Precision Medicine
- Real world data
- Treatment optimization.
- Access to treatment, quality of life.
- Evidence generation for clinical decision.
Keywords: Health, cancer, clinical and translational research, complex clinical trial, study sponsorship, medicine, drugs, surgery, radiotherapy, chemotherapy, imaging, laboratory, patient, pharmacovigilance, quality insurance, biostatistics, biobank, regulatory, quality of life, funding, sequencing, molecular screening platform.- Meetings
Meetings
8 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 11 Mar 2022 Location Brussels, virtual Subject Discussion on Europe's Beating Cancer Plan and breast cancer Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Tove Ernst (Cabinet member)
-
Date 24 Feb 2021 Location Brussels - virtual meeting Subject Exchange of views on Europe’s Beating Cancer Plan, the EU Pharmaceutical Strategy and the availability of medicines. Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 03 Nov 2020 Location Brussels - virtual call Subject Exchange of views on Europe’s Beating Cancer Plan Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Tove Ernst (Cabinet member)
-
Date 19 Feb 2020 Location Brussels Subject challenges of documenting robust evidence for the use of cancer treatments DG Health and Food Safety Attending - Anne Bucher (Director-General)
-
Date 05 Feb 2020 Location Brussels Subject Discussion on Cancer and Europe's Beating Cancer Plan Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
Other Lobbyists -
Date 03 May 2018 Location Brussels Subject HTA Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Vytenis Andriukaitis (Commissioner)
- Annika Nowak (Cabinet member)
Other Lobbyists - European Public Health Association
- European Forum for Primary Care
- European Society for Medical Oncology (ESMO)
- European Hospital and Healthcare Federation
- European Union of General Practitioners / Family Physicians (Union Européenne des Médecins Omnipraticiens / Médecins de Famille)
- Standing Committee of European Doctors
- European Society of Cardiology
- The European Association of Hospital Pharmacists
- Phamaceutical Group of the European Union
-
Date 16 Apr 2018 Location Brussels Subject Discussion Cancer Research DG Health and Food Safety Attending - Xavier Prats Monné (Director-General)
-
Date 05 May 2017 Location Brussels Subject Clinical research Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)
- Meetings